Table 2.

Characteristics for patient profiles analysed in stage 1 of the WWARN PCE^a

Characteristics	All patients (n = 714 patients)	Successful analysis (n = 678 patients)	Unsuccessful analysis (n = 36 patients)
Number of parasite measurements
Median, IQR	5, 5–6	6, 5–7	3, 3–3
Range	3–14	3–14	3–5
< 3	0	0	0
3	37 (5.2%)	2 (0.3%)	35 (97.2%)
4	107 (15%)	107 (15.8%)	0
5	217 (30.4%)	216 (31.9%)	1 (2.8%)
6	182 (25.5%)	182 (26.8%)	0
7	110 (15.4%)	110 (16.2%)	0
≥ 8	61 (8.5%)	61 (9%)	0
Sex
Female	135 (18.9%)	128 (18.9%)	7 (19.4%)
Male	579 (81.1%)	550 (81.1%)	29 (80.6%)
Age (years)
Median, IQR	35, 24–49	34, 23–48	37, 23–44.5
Range	3–96	3–96	14–68
Weight (kg)
Median, IQR	58, 50–67	58, 50.4–67	59, 51.5–68
Range	11–118	11–118	35–80.5
Previous malaria
No	511 (71.6%)	489 (72.1%)	22 (61.1%)
Yes	203 (28.4%)	189 (27.9%)	14 (38.9%)
Days of preceding fever
Median, IQR	4, 3–7	4, 3–7	4, 3–7
Range	0–44b	0–44c	2–14d
Initial parasitaemia (/μL of blood)
Median, IQR	1898, 463–6276	2056, 533–6398	127, 56–555
Range	28–325,294	28–325,294	28–16,748
Treatment
Uncomplicated malaria
Artemether–lumefantrine	320 (44.8%)	301 (44.3%)	19 (52.8%)
Artesunate–mefloquine	115 (16.1%)	111 (16.4%)	4 (11%)
Chloroquine	176 (24.7%)	174 (25.7%)	2 (5.6%)
Severe malaria
Artemether–lumefantrine followed by artesunate (intravenous)	16 (2.2%)	15 (2.2%)	1 (2.8%)
Artesunate (intravenous) followed by artemether–lumefantrine	87 (12.2%)	77 (11.4%)	10 (27.8%)

^aWorldwide Antimalarial Resistance Network’s Parasite Clearance Estimator

IQR: inter-quartile range; kg: kilograms; μL: microlitre

^b18 patients did not have data for days of preceding fever

^c2 patients did not have data for days of preceding fever

^d16 patients did not have data for days of preceding fever